


Catalog# BP-50194

Mirvetuximab soravtansine

Description:

Mirvetuximab soravtansine-gynx (IMGN853) is a folate receptor alpha (FR α)-directed antibody-drug conjugate (ADC) consisting of three components: 1) an anti-FR α monoclonal antibody of IgG1 subtype 2) the small molecule anti-tubulin agent DM4 (a maytansine derivative) and 3) a linker, sulfo-SPDB (1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yl)disulfanyl)butane-2-sulfonic acid) that covalently attaches DM4 to the mirvetuximab antibody. Mirvetuximab soravtansine-gynx has an approximate molecular weight of 150 kDa. The DAR is $n \sim 3.4$. Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage. This product is for research use only. Mirvetuximab soravtansine-gynx has the following structure:



Product Details	
CAS No.	1453084-37-1
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Mirvetuximab (Anti- FOLR1)
Target	folate receptor α (FR α)
ADC cytotoxin (drug)	DM4
Purity	99.7%
DAR	~3.8
Molecular Weight	~150kDa
Endotoxin	<1 EU/mg
Free-drug	0.107 μ g/mg
Formulation	10.246 mg/mL x 97.6 μ L in 10mM Histidine pH=5.5
Purification	Size exclusive column
Storage conditions	Store the undiluted solution at -80°C in the dark to avoid freeze-thaw cycles.